Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Technology At Great Ormond Street Hospital Is Aiding Faster Emergency Referrals To Its Specialist Paediatricians, England
Thanks to the introduction of an innovative IT system at the Children"s Acute Transport Service (CATS) hosted at Great Ormond Street Hospital for Children NHS Trust (GOSH), referring hospitals can now share perfect quality medical data on emergency patients more quickly and securely than ever before.
generic viagra online
Needle Exchange Programs Could Save Texas 'Millions Of Dollars,' Opinion Piece Says
Needle exchange programs (NEPs) "are an inexpensive public health intervention, especially when compared with the social costs of treating individuals with HIV or hepatitis-related chronic liver disease," Maureen Trotter, a pathologist and president of the Taylor-Jones-Haskell County Medical Society, writes in the Abilene Reporter News. She adds that legislation introduced this year in the Texas Legislature "to allow public health departments and organizations to establish disease control programs that provide for the anonymous exchange of used hypodermic needles and syringes for sterile ones, offer education and substance abuse treatment and blood-borne disease testing" failed to come to a floor vote. Trotter further discusses NEPs, citing data on outcomes of NEPs, and writes, "The costs of preventing one case of HIV is estimated between $4,000 and $12,000 via NEPs. The medical cost of treating a person infected with HIV is about $200,000," adding, "These programs, if implemented, could save Texas millions of dollars" (7/12).
News of the day
GPs Deliver Cost Effective Health Care, Australian Medical Association
An OECD report has confirmed that GP-led primary care is a cost effective way to promote good health while sending a warning about the need to better promote general practice as a career. The OECD Health Data 2009 report says despite the growing need for GPs worldwide there is an increasing trend towards specialisation. The number of specialists rose by 60% between 1990 and 2007, compared with only a 23% increase in GPs.
Endocrinology

FDA Approves NovoLog(R) Labeling Update Increasing The Time Patients Can Use And Store NovoLog(R) In Their Pumps From Two Days To Six Days

Diabetes patients taking NovoLog® (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today.[i] The previous label allowed for NovoLog® to be stored in the pump reservoir for two days. This makes NovoLog® the first and only rapid-acting insulin with this extended in-use time. An insulin pump is a small, battery powered device designed to constantly deliver insulin into the patient"s body 24 hours a day according to a preset program. Approximately the size of a pager, the pump system is composed of a reservoir for the insulin, a small battery, the pump, and a thin plastic tube with a needle on the end that passes insulin into the body, called the infusion set. The updated NovoLog® label also states that patients using NovoLog® in their pumps should change the infusion set and the infusion set insertion site at least every three days. The previous label stated that NovoLog® in the pump reservoir, infusion set and the infusion set insertion site be changed at least every 48 hours. The revised label keeps the same recommendation that NovoLog® should be discarded after exposure to temperatures that exceed 37°C (98.6°F). "The ability to go longer between changes of insulin in the pump allows people with diabetes to have more active and flexible lifestyles, which are integral to the success of long-term diabetes management," said Richard R. Rubin, PhD, professor, medicine and pediatrics, The Johns Hopkins University School of Medicine. The label change is based on the FDA"s review of data from Novo Nordisk that showed the stability of NovoLog® in the pump for up to six days. NovoLog® is a rapid-acting insulin analog, meaning it works faster and for a shorter period of time compared with regular human insulin. NovoLog® is also available in FlexPen®, the world"s #1 selling prefilled insulin pen. Diabetes patients who take NovoLog® can eat within 5-10 minutes of use, rather than the typical 30 minutes required with regular human insulin. NovoLog® was first approved by the FDA in 2000 and approved for use in pumps in 2001. Prescribing information for NovoLog® is available by contacting Novo Nordisk or visiting http://www.novolog.com. [i] Revised NovoLog Prescribing Information. "Dosage and Administration." Section 2.3. "Continuous subcutaneous insulin infusion (CSII) by external pump." NovoLog® is a registered trademark of Novo Nordisk A/S. Novo Nordisk


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009